US 12,263,166 B2
Methods of treating cancers having a BRCA1 and/or BRCA2 mutation(s)
Alan D'Andrea, Winchester, MA (US); and Kah Suan Lim, Boston, MA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed on Jul. 7, 2022, as Appl. No. 17/811,282.
Application 17/811,282 is a continuation of application No. 16/755,686, granted, now 11,413,288, previously published as PCT/US2018/055855, filed on Oct. 15, 2018.
Claims priority of provisional application 62/719,276, filed on Aug. 17, 2018.
Claims priority of provisional application 62/580,058, filed on Nov. 1, 2017.
Prior Publication US 2023/0093238 A1, Mar. 23, 2023
Int. Cl. A61K 31/506 (2006.01); A61K 31/423 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/713 (2006.01); A61K 38/17 (2006.01); A61K 38/45 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/40 (2006.01); C12N 15/113 (2010.01)
CPC A61K 31/506 (2013.01) [A61K 31/423 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/713 (2013.01); A61K 38/1761 (2013.01); A61K 38/45 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/40 (2013.01); C12N 15/1137 (2013.01); C12Y 203/02 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01)] 12 Claims
 
1. A method for treating a human subject having, or at risk of developing, a cancer, the method comprising administering to the human subject an effective amount of a USP1 inhibitor and a PARP inhibitor, wherein the human subject is identified as having a BRCA1 and/or BRCA2 mutation.